Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Olema Pharmaceuticals Inc.
Headquarters: San Francisco, CA, United States of America
Website: https://olema.com/
Year Founded: 2007
Status: Public
Industry Sector: HealthTechnology
CEO: Sean P. Bohen, MD, PhD
Number Of Employees: 74
Enterprise Value: $375,426,785
PE Ratio: -2
Exchange/Ticker 1: NASDAQ:OLMA
Exchange/Ticker 2: N/A
Latest Market Cap: $298,615,616
BioCentury | Feb 19, 2025
Management Tracks
Mehta named CMO, Greenberg CBO at Nura Bio
Plus: Shawnte Mitchell joins Olema as chief legal and updates from Loqus23, Pheast, Crafton, Eupraxia and more
BioCentury | Dec 7, 2024
Finance
Revolution, Janux prep for next steps with follow-on cash
In BioCentury’s Public Equity Report: Oncology companies tap public markets for more than $1.2B, while Olema draws $250M PIPE for Novartis combo trial
BioCentury | May 2, 2024
Management Tracks
Wallace leaving Monte Rosa for CEO job
Plus: Ipsen names Keira Driansky president of North America, and updates from Immunome and SFA
BioCentury | Oct 18, 2023
Management Tracks
eTheRNA names Sagaert CEO, Dekkers as chairman
Plus: Cyrus Harmon becomes CEO at Vilya, and updates from Epic Bio, Exscientia, Pliant, Cognito, Pattern
BioCentury | Sep 5, 2023
Deals
Sept. 5 Quick Takes: Moulder’s Zenas in regional deal with BMS for bispecific
Plus: Beam moves base editors into the clinic and updates on Star, Tivdak, Olema and Insmed’s Arikayce
BioCentury | Dec 10, 2022
Product Development
Lessons emerging from the evolving SERD landscape
AstraZeneca’s camizestrant data cap progress in oral SERDs, a class that is figuring out how to demonstrate benefit against changing competition
BioCentury | Oct 26, 2022
Data Byte
AstraZeneca’s Phase II SERD data raise hopes for the class
After recent setbacks of other SERDs, camizestrant’s Phase II breast cancer win is welcome news for the class
BioCentury | Feb 1, 2022
Management Tracks
Senti Bio, Sangamo alum Lee joins Lyell as CSO
Plus Leaming and Posner retire from Biogen’s board, Bourdon moves to Leo, and updates from Keros, NeoTX and more
BioCentury | Dec 2, 2020
Finance
Data Byte: IPO queue picks up post-election
Plus: Harbour BioMed files to raise up to $230.4M in HK IPO
BioCentury | Nov 20, 2020
Finance
Nov. 19 Quick Takes: Olema’s IPO, plus venture rounds for Imago, Medable, China deal for AUM-Newsoara and Qiming’s $1.2B fund
Olema posts big gain after $209M IPOShares of Olema Pharmaceuticals Inc. (NASDAQ:OLMA) rose $30 (158%) to $49 in their first day of trading after the company raised $209 million through the sale of 11
Items per page:
1 - 10 of 14